Alyeska Investment Group
RVNC

Alyeska Investment Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Alyeska Investment Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-92,417
Closed -$2.5M – 527
2022
Q3 		$2.5M Buy
+92,417
New +$1.87M 0.03% 308
2020
Q1 		– Sell
-398,362
Closed -$6.46M – 493
2019
Q4 		$6.46M Buy
+398,362
New +$6.18M 0.09% 205
2014
Q4 		– Sell
-32,360
Closed -$626K – 538
2014
Q3 		$626K Sell
32,360
-27,640
-46% -$720K 0.01% 354
2014
Q2 		$2.04M Buy
+60,000
New +$1.88M 0.05% 312

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alyeska Investment Group's RVNC Position: Q4 2022 in Review

Alyeska Investment Group sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 92,417 shares — an estimated $2.5M sold.

Alyeska Investment Group first reported a position in RVNC in Q2 2014 and held it in 4 quarters. The position peaked at $6.46M in Q4 2019. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

  • Alyeska Investment Group reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 92,417 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $2.5M.
  • Alyeska Investment Group first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 4 quarters.
  • Alyeska Investment Group's Revance Therapeutics, Inc. position peaked at $6.46M in Q4 2019.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on Alyeska Investment Group's 13F filing for Q4 2022, filed 14 Feb 2023.